Patent · US Active

Use of a TRPM5 inhibitor to regulate insulin and GLP-1 release

US8193168B2 · kind B2 · utility

0Cited by

19References

22Claims

0Family size

Assignee

Redpoint Bio Corporation · US

Inventors

S. Paul Lee · Phoenix, US
Peihong Zhou · East Brunswick Township, US
M. N. Tulu Buber · Newtown, US
Rok Cerne · Lawrenceville, US
Robert W. Bryant · Princeton, US
F. Raymond Salemme · Yardley, US
Gillian Morgan · Brussels, BE

Key dates

Filing date	Feb 4, 2008
Grant date	Jun 5, 2012
Priority date	—
Expiry date	Feb 4, 2028

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is directed to methods of enhancing insulin release, GLP-1 release, and insulin sensitivity, methods of increasing insulin gene expression, methods of decreasing gastric secretion and emptying and glucagons secretion, and methods of inhibiting food intake, and methods of treating diabetes mellitus, insulin resistance syndrome, hyperglycemia, and obesity comprising administering to a subject an effective amount of a TRPM5 inhibitor.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.